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Abstract
Background: Mushrooms are well recognized for their culinary properties as well as for their potency to enhance
immune response. In the present study, we evaluated anti-inflammatory properties of an edible oyster mushroom
(Pleurotus ostreatus) in vitro and in vivo.
Methods: RAW264.7 murine macrophage cell line and murine splenocytes were incubated with the oyster
mushroom concentrate (OMC, 0-100 μg/ml) in the absence or presence of lipopolysacharide (LPS) or concanavalin
A (ConA), respectively. Cell proliferation was determined by MTT assay. Expression of cytokines and proteins was
measured by ELISA assay and Western blot analysis, respectively. DNA-binding activity was assayed by the gel-shift
analysis. Inflammation in mice was induced by intraperitoneal injection of LPS.
Results: OMC suppressed LPS-induced secretion of tumor necrosis factor-a (TNF-a, interleukin-6 (IL-6), and IL-
12p40 from RAW264.7 macrophages. OMC inhibited LPS-induced production of prostaglandin E2 (PGE2) and nitric
oxide (NO) through the down-regulation of expression of COX-2 and iNOS, respectively. OMC also inhibited LPS-
dependent DNA-binding activity of AP-1 and NF-B in RAW264.7 cells. Oral administration of OMC markedly
suppressed secretion of TNF-a and IL-6 in mice challenged with LPS in vivo. Anti-inflammatory activity of OMC was
confirmed by the inhibition of proliferation and secretion of interferon-g (IFN-g), IL-2, and IL-6 from concanavalin A
(ConA)-stimulated mouse splenocytes.
Conclusions: Our study suggests that oyster mushroom possesses anti-inflammatory activities and could be
considered a dietary agent against inflammation. The health benefits of the oyster mushroom warrant further
clinical studies.
Background
Systemic inflammation has been linked to the pathogen-
esis of a variety of diseases including endotoxemia and
sepsis [1]. Pro-inflammatory cells, mainly macrophages,
monocytes, or other host cells, respond to invading
pathogens by releasing pro-inflammatory mediators,
including tumor necrosis factor-a (TNF-a), interleukin-
6 (IL-6), IL-12, cyclooxygenase-2 (COX-2) and nitric
oxide (NO) [2-5]. Mechanistically, lipopolysaccharide
(LPS), a constituent of the cell wall of gram-negative
bacteria, interacts with toll-like receptor 4 (TLR4),
which is expressed on pro-inflammatory cells [6,7]. The
interaction between LPS and the TLR4 receptor com-
plex results in the activation of intracellular signaling
through MyD88 and TRIF pathways leading to the acti-
vation of transcription factors NF-B and AP-1 and the
expression of TNF-a and IL-6 [8,9]. LPS also induces
expression of IL-12 in macrophages through the NF-B
pathway [10,11], and the AP-1 binding site was identi-
fied in the promoter region of IL-12p40 [12]. Moreover,
LPS-induced expression of COX-2 and inducible nitric
oxide synthase (iNOS) is also controlled through NF-B
and AP-1 [13], and LPS-induced expression of iNOS
and IL-6 require phosphorylation of STAT3 [14,15].
Therefore, the suppression of the release of pro-inflam-
matory mediators, through the modulation of intracellu-
lar signaling in immune cells, could be used for the
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of the possible strategies to suppress systemic inflamma-
tion is the employment of natural compounds such as
botanicals, bioactive food components, or functional
foods.
Mushrooms have been used, as a source of food and
for their medicinal (generally anticancer) properties,
since ancient times [16]. A number of biologically active
compounds, including polysaccharides, vitamins, ter-
penes, steroids, amino acids, and trace elements, have
been identified in different mushroom species [17]. Poly-
saccharides, mainly a-o rb-glucans, protein-bound
polysaccharides, or glycoproteins, demonstrated immu-
nomodulatory activities through (i) increased production
of cytokines (IL-10, IL-12p70 and IL-12p40) by dendritic
cells (DC), (ii) activation of natural killer (NK) cells, and
(iii) increased production of TNF-a, IL-1, IL-6, IL-8, IL-
12p40, and NO, and expression of iNOS by macro-
phages [18]. The majority of these studies were per-
formed with medicinal (Ganoderma lucidum, Phellinus
linteus)o re d i b l e( Agaricus blazei, Grifola frondosa)
mushrooms [18]. As recently demonstrated, an edible
white button mushroom (Agaricus bisporus) enhanced
N Kc e l la c t i v i t yi nm i c et h r o u g ht h ei n c r e a s e dp r o d u c -
tion of IFN-g which induced maturation of dendritic
cells, and TNF-a, which increased production of IL-12
[19,20].
Oyster mushrooms (Pleurotus species) belong to the
world of consumed mushrooms that, in addition to their
nutritional value, demonstrate health-promoting (antiox-
idant, anti-atherosclerotic, anticancer and immunomo-
dulatory) effects [21-24]. Glycosphingolipid, isolated
from Pleurotus eryngii, induced secretion of IFN-g and
IL-4 from T-cells [25], whereas b-glucan demonstrated
an anti-inflammatory response in a model of acute coli-
t i si nr a t sw h e ni s o l a t e df r o mPleurotus pulmonarius,
and, when isolated from Pleurotus ostreatus,i n h i b i t e d
leukocyte migration to acetic acid-injured tissues
[26,27]. An extract from Pleurotus florida suppressed
inflammation, as demonstrated by the decrease in paw
thickness in carrageen-induced acute inflammation and
formalin-induced chronic inflammation [28]. However,
the molecular mechanisms responsible for the anti-
inflammatory properties of the oyster mushroom were
not addressed. In the present study, we examined the
anti-inflammatory effects of the oyster mushroom on
LPS-stimulated RAW264.7 macrophages, isolated mur-
ine splenocytes, and in mice challenged with LPS.
Methods
Materials
Oyster mushrooms were provided by Forest mush-
rooms, Inc. (Saint Joseph, MN, USA). Oyster mush-
rooms were grown at 17-18°C, relative humidity 90-95%
and 850 ppm CO2 with diffuse daylight during the day
and no artificial light at night. Oyster mushrooms were
harvested at 5 days of age and shipped O/N at 4°C to
the laboratory for the further processing. Lipopolysac-
charide (LPS) and concanavalin A were purchased from
Sigma (St. Louis, MO, USA), and heparin was purchased
from Abraxis Pharmaceutical Products (Schaumburg, IL,
USA).
Preparation of Oyster mushroom concentrate (OMC)
Fresh oyster mushrooms were ground and then lyophi-
lized by FreeZone
® 4.5 Liter Freeze Dry Systems, and
the dry biomass was stored at 4°C. The ground materials
were then re-suspended in distilled water at the concen-
tration 5 mg/ml and incubated overnight at 4°C. The
suspension was centrifuged at 7000 rpm (5200 g) for 10
minutes, and the supernatant was sterilized through a
0.22 μm filter. This water-soluble lyophilized oyster
mushroom was labeled oyster mushroom concentrate
(OMC), and its concentration corresponded to the origi-
nal lyophilized oyster mushroom. An Osmomat μ OSM-
ETTE™ (Precision Systems Inc, Natick, MA, USA) was
used to determine osmolarity of the OMC extract (26
mOsm/kg) and Orion 2-Star Benchtop pH meter
(Water Analysis Instruments, Beverly, MA, USA) for pH
determination (pH = 6.2).
Cells
The murine macrophage cell line (RAW264.7) was
obtained from ATCC (Manassas, VA, USA). The cells
were maintained in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum
(FBS), 100 units/ml of penicillin, and 100 μg/ml of
streptomycin (all from Gibco, Grand Island, NY, USA)
in a humidified atmosphere at 37°C in 5% CO2.
Cell proliferation-viability
RAW264.7 cell were treated with OMC (0-100 μg/ml) at
indicated times and cell proliferation-viability was evalu-
ated by MTT assay as previously described [29].
Expression of pro-inflammatory mediators in RAW264.7
cells
RAW264.7 cells were pretreated with OMC (0-100 μg/
ml) for 24 hours, followed by stimulation with 1 μg/ml
of LPS or TNF-a 100 ng/ml (R&D Systems, Minneapo-
lis, MN, USA) for an additional 24 hours in medium
without FBS and antibiotics. Then the medium was col-
lected and centrifuged to remove debris. Secretion of
TNF-a, IL-6, IL-12p40 (Biolegend, San Diego, CA,
USA), and PGE2 (R&D Systems, Minneapolis, MN,
USA) was determined by ELISA; the release of NO was
determined by Griess reagent (Sigma, St. Louis, MO,
USA) as previously described [29].
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RAW264.7 cells were pretreated with OMC (0-100 μg/
ml) for 24 hours followed by incubation with LPS (1 μg/
ml) for an additional 30 minutes (STAT3) or 24 hours
(COX-2, iNOS). Whole cell extracts were prepared and
subjected to Western blot analysis with anti-COX-2,
anti-iNOS, anti-phospho-STAT3, and anti-STAT-3 anti-
bodies (Santa Cruz Biotechnology, Santa Cruz, CA,
USA), respectively, as we previously described [29]. The
equivalent amount of proteins was verified by reprobing
the blot with anti-actin antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). The expression of each
protein was detected by the ECL Western blotting
detection system (Amersham Biosciences, Buckingham-
shire, UK).
Electrophoretic mobility shift assay (EMSA)
EMSA for AP-1 and NF-B was performed with nuclear
extracts isolated from RAW264.7 cells pretreated with
OMC (0-100 μg/ml) and stimulated with LPS (1 μg/ml)
at indicated times as previously described [30]. Briefly,
nuclear extracts were incubated with
32P-labelled NF-B
or AP-1 oligonucleotide probes, and DNA-binding was
detected by autoradiography after the separation of
DNA-nuclear protein complexes on PAGE gel as pre-
viously described [29]. Oligonucleotide probes containing
consensus sequences for AP-1 and NF-Bb i n d i n gs i t e s
were purchased from Promega (Madison, WI, USA).
Densitometric analysis
Autoradiograms of the Western blots and gel shifts were
scanned with HP scanjet 5470c scanner. The optical
densities on the films were quantified and analyzed with
the UN-SCAN-IT software (Silk Scientific, Orem, UT).
The ratios of COX-2/b-actin, iNOS/b-actin and phos-
pho-STAT3/STAT3 were calculated by standardizing
the ratios of each control to the unit value.
Animal experiments
Eight- to ten-week-old female Balb/C mice were
obtained from the Jackson Laboratory, (Bar Harbor, ME,
USA) and were maintained at the Methodist Research
Institute Animal Facility which is accredited and certi-
fied by USDA with PHS assurance (A3772-01). Animal
experiments were fully approved by the Methodist
Research Institute Animal Research Committee (ARC
2007-17). All animals were housed in plastic cages (4
mice/cage) with free access to drinking water and
NIH#31M pellet diet ad libitum. After one week of
acclimatization, the mice were randomly divided into
experimental and control groups. To avoid the interfer-
ence of food in the absorption of the treatment agent,
the mice were starved for 3 hours before the experiment
started. In the next step OMC (1000 mg/kg of body
weight) or distilled water was administered by intragas-
trical gavage. The concentration of 1000 mg/kg of the
oyster mushroom extract was previously used for the
inhibition of acute and chronic inflammation in mice
[28]. After one hour, the mice received intraperitoneal
injection of LPS (0.1 mg/kg of body weight). After an
additional 90 minutes, the blood was withdrawn by the
retroorbital venipuncture, and plasma was isolated by
centrifugation. All animals were euthanized by CO2as-
phyxiation. Plasma TNF-a and IL-6 levels were deter-
mined by ELISA according to the manufacturer’s
instructions (Biolegend, San Diego, CA, USA).
Proliferation of splenocytes
Balb/C mice were sacrificed and their spleens were
removed and homogenized aseptically. 2.5 × 10
4 spleen
cells were cultured in 96-well plates in triplicates in
complete medium consisting of RPMI 1640 supplemen-
ted with 10% FBS, 1% [+]-glutamine, 100 units/ml of
penicillin, and 100 μg/ml of streptomycin (all from
Gibco, Grand Island, NY, USA). The cells were cultured
i nt h ep r e s e n c eo fc o n c a n a v a l i nA( 5μg/ml) and OMC
(0-100 μg/ml) for 72 hours, followed by the addition of
cell proliferation reagent WST-1 (Roche Applied
Science, Indianapolis, IN, USA) for another 3 hours.
After that, the microplate was read at 450 nm by a Ver-
samax microplate reader (Molecular Devices, Sunnyvale,
CA, USA).
Cytokine production in splenocytes
1×1 0
5 spleen cells were cultured in duplicate in 24-
well plates containing RPMI 1640 medium supplemen-
ted with 10% FBS, 1% [+]-glutamine, 100 units/ml of
penicillin and 100 μg/ml of streptomycin (all from
Gibco, Grand Island, NY, USA). The cells were cultured
i nt h ep r e s e n c eo fc o n c a n a v a l i nA( 5μg/ml) and OMC
(0-100 μg/ml) for 72 hours, and the medium was col-
lected and centrifuged to remove debris. Secretion of
IFN-g, IL-2 and IL-6 was determined by ELISA (Biole-
gend, San Diego, CA, USA).
Analysis of glucans in lyophilized oyster mushrooms and
OMC
a-a n db-glucans in lyophilized oyster mushrooms and
OMC were determined by acidic and enzymatic hydroly-
sis using the Mushroom and Yeast beta-glucan assay
according to manufacturer’s protocol (Megazyme, Wick-
low, Ireland).
LC/UV/MS analysis
Lyophilized oyster mushrooms were extracted with
water and analyzed by liquid chromatography/ultraviolet
spectrometry/mass spectrometry (LC/UV/MS). The LC/
UV/MS methods for natural compounds were developed
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Products Program (NUANPP), and performed on an
Agilent 1100 Series LC/UV/MSD system equipped with
a quaternary pump, diode array detector (DAD), ther-
mostatted column compartment, degasser, MSD ion
trap with an electrospray ion source (ESI) and HP
ChemStation software, Bruker Daltonics 4.2 and DataA-
nalysis 4.2 software. HPLC separation was performed
with the mobile phase consisting of solvent water and
methanol in gradient. The wavelength of UV detection
was set at 210 and 254 nm. Column compartment was
set at 25°C. The flow rate was 1.0 mL/min. The electro-
spray ion mass spectrometer (ESI-MS) was operated
under positive ion and optimized collision energy level
of 60%, scanned from m/z 100 to 600. ESI was con-
ducted using a needle voltage of 3.5 kV. High-purity
nitrogen (99.999%) was used as dry gas, and a nebulizer
was used at a flow rate of 12 L/min; capillary tempera-
ture was 350°C. Helium, at 60 psi, was used as the colli-
sion gas. The ESI interface and mass spectrometer
parameters were optimized to obtain maximum
sensitivity.
Statistical Analysis
D a t aa r em e a n±S . Da n dw e r ea n a l y z e db yA N O V Ao r
Student’s t-test. Results were considered significant if P
≤ 0.05.
Results
OMC suppresses LPS-dependent induction of cytokines
and inflammatory mediators in macrophages
To assess whether OMC possesses anti-inflammatory
activity in vitro,w ef i r s td e t e r m i n e dw h e t h e rO M C
affects the production of pro-inflammatory cytokines in
macrophages exposed to inflammatory stimuli. As seen
in Table 1 OMC treatment significantly suppressed
LPS-dependent production of TNF-a, IL-6, and IL-12,
respectively, in a dose response manner. This effect was
not caused by the cytotoxicity of OMC because OMC
did not affect viability of RAW264.7 cells; the only slight
inhibition of cell proliferation (viability) was observed
after 48 and 72 hours at the highest concentration (100
μg/ml) of OMC treatment (Figure 1). Therefore, the
inhibition of production of TNF-a, IL-6, and IL-12 by
62%, 93% and 64%, respectively, at 100 μg/ml of OMC
(Table 1) is mediated by the anti-inflammatory activity
of OMC.
Next, we evaluated whether OMC suppresses LPS-
dependent production of inflammatory mediators PGE2
and NO. OMC inhibited production of PGE2 in
RAW264.7 cells in a dose response manner (Figure 2A).
To determine if this effect is caused by the inhibition of
COX-2, we evaluated the expression of COX-2 by Wes-
tern blot analysis. Therefore, LPS-induced expression of
COX-2 in RAW 264.7 cells was markedly suppressed by
the OMC treatment (Figure 2B). Moreover, OMC sup-
pressed LPS-dependent production of NO in RAW264.7
cells (Figure 2C). As expected, this effect was directly
linked to the down-regulation of iNOS by OMC in LPS-
challenged macrophages (Figure 2D). To evaluate
whether the effect of OMC is anti-inflammatory and is
not mediated by the inhibition of endotoxin binding to
TLR4 or inhibition of TLR4 signaling, we stimulated
RAW264.7 cells with TNF-a.A ss e e ni nF i g u r e2 E ,
TNF-a-dependent induction of IL-6 was markedly sup-
pressed by the OMC treatment. Each of these screens
showed that OMC suppressed proinflammatory
response, LPS dependent production of cytokines and
inflammatory mediators, in RAW264.7 macrophages.
Effect of OMC on the LPS-dependent induction of
transcription activity of AP-1, NF-B, and STAT3
As indicated, an inflammatory response in macrophages
can be mediated through COX-2 and iNOS. The
Table 1 OMC Suppresses LPS-induced inflammatory
response in RAW264.7 macrophages.
TNF-a [ng/ml] IL-6 [ng/ml] IL-12 [pg/ml]
Control 3.96 ± 0.15 1.73 ± 0.07 1.65 ± 1.51
LPS + 0 μg/ml OMC 15.35 ± 1.41† 16.12 ± 0.12† 108.75 ± 3.37†
LPS + 12.5 μg/ml OMC 12.99 ± 0.73* 9.54 ± 0.13* 68.01 ± 3.51*
LPS + 25 μg/ml OMC 11.59 ± 0.30* 6.20 ± 0.63* 58.55 ± 3.91*
LPS + 50 μg/ml OMC 9.04 ± 0.15* 4.18 ± 0.03* 47.41 ± 3.60*
LPS + 100 μg/ml OMC 5.87 ± 0.11* 1.16 ± 0.21* 39.18 ± 5.18*
The data are means ± S.D. of two independent experiments, repeated
minimally twice.
† p < 0.05 ANOVA, LPS vs control
* p < 0.05 ANOVA, LPS vs OMC
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Figure 1 Effect of OMC on viability of macrophages. RAW264.7
cells were treated with OMC (0-100 μg/ml) for 24, 48 and 72 hours
and cell proliferation-viability determined as described in Materials
and Methods. The data are means ± S.D., n = 3-4.
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Figure 2 Effect of OMC on LPS-induced PGE2 and NO secretion and COX-2 and iNOS expression in RAW264.7 cells. (A) PGE2 and (C) NO
secretion were determined in cell culture media from RAW264.7 cells treated with OMC and LPS as described in Materials and Methods. The data
are means ± S.D. of two independent experiments, repeated minimally twice. Means without a common letter differ, P < 0.05. Expression of (B)
COX-2 and (D) iNOS were determined in whole cell lysates from RAW264.7 cells treated with OMC and LPS as described in Materials and
Methods. The equal protein loading was verified with anti-b-actin antibody. The results are representative of three separate experiments. (E)
Secretion of IL-6 was determined in cell culture media from RAW264.7 cells treated with OMC and TNF-a as described in Materials and Methods.
The data are means ± S.D. of two independent experiments, repeated minimally twice. Means without a common letter differ, P < 0.05.
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scription factors AP-1, NF-B, and STAT3 [15,30,31].
Nuclear extracts were prepared and EMSA with AP-1
and NF-B performed. We observed that LPS-depen-
dent induction of AP-1 binding activity was markedly
suppressed by OMC in a dose-response manner (Figure
3A). On the other hand, LPS-dependent activation of
NF-B was only slightly reduced at 100 μg/ml of OMC
(Figure 3B). Moreover, LPS also stimulated activity of
STAT3, as demonstrated by the increased phosphoryla-
tion of STAT3 by Western blot analysis (Figure 3C).
However, this LPS-dependent activation of STAT3 was
not affected by the OMC (Figure 3C). In sum, the inhi-
bition of an inflammatory response in macrophages is
mediated by suppression of transcription activity of AP-
1 and NF-B.
Effect of OMC on systemic inflammation in mice
To determine whether OMC suppresses inflammatory
response in vivo we evaluated OMC efficacy in a mouse
model of LPS-induced endotoxemia. Results showed
that intraperitoneal injection of LPS (0.1 mg/kg) caused
the significant elevation of plasma TNF-a at 90 minutes
after the LPS challenge, whereas in mice pretreated by
oral application of OMC (1000 mg/kg), plasma TNF-a
levels decreased by 58.7% (Figure 4A). Moreover, we
have found that OMC suppressed the LPS-dependent
induction of the plasma IL-6 levels in mice by 26.9%
(Figure 4B). Therefore, our data suggest that OMC pos-
sesses anti-inflammatory activity in vivo.
OMC possesses immunosuppressive activity
To determine the immunosuppressive potential of
OMC, we evaluated the effect of OMC on mitogen-sti-
mulated splenocyte proliferation in vitro. ConA-depen-
dent induction of splenocyte proliferation was
significantly reduced by OMC (Figure 5A), suggesting
immunosuppressive activity of OMC. Because the inhi-
bition of splenocyte proliferation could be associated
with suppressed production of proinflammatory cyto-
kines by lymphocytes (B-cells), we next evaluated the
levels of IFN-g, IL-2 and IL-6 in splenocytes stimulated
w i t hC o n Ai nt h ep r e s e n c eo fO M C .W ef o u n dt h a t
OMC markedly suppressed ConA-dependent production
of IFN-g and IL-2, suggesting that OMC modulates
Th1-mediated immune response (Figure 5B and 5C). In
addition, OMC suppressed ConA-dependent production
of IL-6 in splenocytes (Figure 5D), further confirming
anti-inflammatory activity of OMC.
Analysis of biologically active compounds in OMC
Previous chemical studies on the oyster mushroom indi-
cate that water-soluble polysaccharides [32], amino
acids, and nucleotides [33] are its major natural
compounds, along with minor low polar sterols, ter-
penes [34], and vitamins that include water soluble vita-
mins B and C, and fat-soluble vitamin D [35]. The
chemical composition of mushrooms directly depends
on their source because different lineages of the same
mushroom demonstrated diverse activities [36-38].
A
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Figure 3 Effect of OMC on LPS-dependent activation of AP-1,
NF-B and STAT3 in RAW264.7 cells. (A) AP-1 and (B) NF-B
DNA-binding activity was determined by gel shift analysis in nuclear
extracts isolated from RAW264.7 cells pretreated with OMC (0, 50
100 μg/ml) for 24 hours followed by the stimulation with LPS (1 μg/
ml) for an additional 30 minutes. Nuclear extracts were subjected to
EMSA with a [
32P]-labeled AP-1 or [
32P]-labeled NF-B probe as
described in Materials and Methods. The specificity of DNA-binding
was confirmed by competitive gel shift with cold AP-1, NF-B, or
unrelated DNA (URL). (C) STAT3 activity was evaluated in whole cell
extracts treated with OMC for 24 hours and LPS for 30 minutes by
Western blot analysis with anti-phospho-STAT3 antibody. The equal
protein loading was verified with anti-STAT3 antibody. The results
are representative of three separate experiments.
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cessing, and storage conditions are crucial factors that
can influence the biological activity of mushrooms and
their extracts [39,40]. Acidic and enzymatic hydrolysis
of lyophilized oyster mushrooms and OMC was per-
formed as described in Materials and Methods and
demonstrated that lyophilized oyster mushrooms con-
tain 63.5% and 0.3%, whereas OMC contains 5.6% and
0.3% of b-glucans and a-glucans, respectively. In addi-
tion, LC/UV/MS analysis of OMC demonstrated the
presence of amino acids isoleucine, leucine, tyrosine,
and phenylalanine, and cytidine monophosphate (CMP),
adenosine monophosphate (AMP), guanosine monopho-
sphate (GMP) and vitamin B2 (not shown).
Discussion
In this study, we have evaluated anti-inflammatory activ-
ities of the oyster mushroom concentrate (OMC). Here
we show that i) OMC markedly suppressed LPS-depen-
dent production of TNF-a, IL-6, and IL-12 in macro-
phages; ii) OMC inhibited LPS-induced production of
PGE2 and NO through the downregulation of expression
of COX-2 and iNOS in macrophages, respectively; iii)
OMC suppressed LPS-dependent activation of AP-1 and
NF-B; iv) OMC inhibited plasma levels of TNF-a and
IL-6 in a mouse model of LPS-induced endotoxemia; v)
OMC inhibited ConA-induced splenocyte proliferation
and production of IFN-g, IL-2, and IL-6; and vi) chemi-
cal analysis demonstrated the presence of a-a n db-glu-
cans, isoleucine, leucine, tyrosine, phenylalanine, AMP,
CMP, GMP, and vitamin B2 in OMC. The results pre-
sented in this study are the first to demonstrate that
OMC inhibits the inflammatory response in macro-
phages, possesses immunosuppressive activity, and inhi-
bits inflammation in mice.
The immunomodulatory effects of mushrooms are
usually associated with the stimulation of the immune
system by a variety of polysaccharides. These effects
include maturation of dendritic cells, stimulation of nat-
ural killer (NK) cell activity, and the activation of T and
B lymphocytes [18,41]. On the other hand an acidic
polysaccharide isolated from Phellinus linteus (PL)
decreased IL-2, IFN-g, and TNF-a production in spleno-
cytes [42]. Methanol extract from Pleurotus florida
demonstrated anti-inflammatory activities in vivo;h o w -
ever, the mechanism of its activity was not addressed
[28]. Interestingly, Yu et al recently demonstrated an
induction of the immune response by the stimulation of
the TNF-a production in RAW264.7 cells treated with
the oyster mushroom Pleurotus eryngii [43]. In contrast
to Yu et al[43] our data with the oyster mushroom
Pleurotus ostreatus (oyster mushroom concentrate,
OMC) demonstrates the opposite effect, inhibition of
LPS-induced TNF-a production in RAW264.7 cells trea-
ted with OMC. Moreover, OMC demonstrated its anti-
inflammatory effect by the inhibition of IL-6, IL-12,
PGE2, and NO production in RAW264.7 cells. Mechan-
istically, these effects were mediated by the downregula-
tion of expression of COX-2 and iNOS through the
inhibition of transcriptional activity of AP-1 and NF-B.
In addition, OMC also suppressed plasma levels of
TNF-a and IL-6 in mice challenged with LPS. Although
Yu et al[43] did not detect any changes in the ConA-
induced secretion of IFN-g from splenocytes isolated
from mice fed with 1% oyster mushroom for 4 weeks,
our data demonstrate that OMC suppressed ConA-
induced proliferation as well as the secretion of IFN-g,
IL-2, and IL-6 from mouse splenocytes. The opposing
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Figure 4 OMC reduces LPS-induced cytokine production in
vivo. (A) TNF-a and (B) IL-6 were determined in plasma in mice
treated with OMC (1000 mg/kg) and LPS (0.1 mg/kg) as described
in Materials and Methods. The data are means ± S.D, n = 3-6. Means
without a common letter differ, P < 0.05.
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Page 7 of 10results from the Yu et al study [43] and our study could
be caused by several factors. Although the preparation
of the oyster mushrooms in both studies is practically
identical (freeze drying of the fresh mushrooms), in our
study, we used a different strain of the oyster mush-
room, Pleurotus ostreatus. In addition, we used a water
extract (OMC) where insoluble particles were removed
by the filtration, whereas Yu et al[43] dissolved freeze-
dried oyster mushroom in DMSO and used the whole,
unfiltered extract. If, however, the same strain of mush-
room had been used, the presence and amount of the
biologically active compounds could be different. As
mentioned above, the chemical composition of different
lineages of the same mushroom could be dissimilar
[36-38]. In addition, the conditions of growing, harvest-
ing, processing, and storaging also affect the composi-
t i o n ,a n d ,t h e r e f o r e ,t h eb i ological activity of the
mushrooms [39,40].
In our study, we analyzed the chemical composition of
OMC, and we identified the water-soluble a- and b-glu-
cans and small organic molecules. Therefore, this analy-
sis could help develop a specific “fingerprint” for the
biologically active mushrooms with particular activities.
We previously tested the biological activities of
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the mushroom with the highest biological activity,
which we then selected for use in our study (unpub-
lished results). A more comprehensive chemical analysis
of the OMC and further bioguided fractionation would
enable a better understanding of the bioactives.
The anti-inflammatory activity of OMC can be attrib-
uted to different compounds. As previously mentioned,
OMC contains the amino acids isoleucine, leucine, tyro-
sine, and phenylalanine. Interestingly, the original study
published 25 years ago, demonstrated anti-inflammatory
activity of isoleucine and leucine and suggested that this
anti-inflammatory activity is related to interference with
the action and/or synthesis of prostaglandins [44].
Another compound with anti-inflammatory activity that
we identified in OMC is vitamin B2. As recently demon-
strated, vitamin B2 suppressed TNF-a,I L - 1 ,I L - 6 ,a n d
NO plasma levels and downregulated expression of
iNOS in livers in mice challenged with LPS [45,46]. As
previously mentioned, the most abundant compounds in
mushrooms are glucans, and their presence is associated
with the stimulation of the immune system [18]. How-
ever, OMC contains 5.8% of water-soluble glucans
(5.56% of b-glucans and 0.26% of a-glucans). Therefore,
it is possible that these glucans are responsible for the
anti-inflammatory activity of the oyster mushroom. As
recently demonstrated, water soluble b-glucans from
other edible mushrooms demonstrated anti-inflamma-
tory activity through the inhibition of NO production in
activated macrophages (Collybia dryophila) [47], the
inhibition of leukocyte migration to injured tissues
(Pleurotus pulmonarius) [26], and the inhibition of
edema (Agaricus blazei) [48]. In addition, an insoluble
b-glucan (pleuran) from Pleurotus ostreatus suppressed
inflammation in an animal model of colitis [27].
Conclusions
In conclusion, the results of our study show that the
edible oyster mushroom possesses anti-inflammatory
activity. As such, the mushroom and its extract or con-
centrate, such as OMC, can be considered a functional
food that has the potential to control inflammation.
Although the biological activity is now better under-
stood, we next seek to identify the responsible biologi-
cally active compounds. Further studies elucidating the
exact mechanism(s) responsible for the anti-inflamma-
tory activity of this culinary mushroom are necessary.
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